Trifluoperazine

Chlordiazepoxide and Trifluoperazine combines an anxiolytic benzodiazepine with a high-potency phenothiazine antipsychotic. Trifluoperazine blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, subduing agitation and delusional thinking, while chlordiazepoxide modulates GABAA receptors to control anxiety and somatic tension. Indicated for anxiety states complicated by somatic obsessions, severe agitation, or mild psychotic symptoms.

Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.

Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.